Article Text

PDF
THU0142 Matrix metalloproteinase-3 and antibodies (IGG) against oxidized low-density lipoprotein levels in patients with rheumatoid arthritis
  1. E Gerasimova,
  2. T Popkova,
  3. M Cherkasova,
  4. E Alexandrova,
  5. A Novokov
  1. V.A.NASONOVA Research Institute of Rheumatology, Moscow, Russian Federation

Abstract

Background Rheumatoid arthritis (RA) is associated with an unexplained increased cardiovascular risk. Matrix metalloproteinase-3 (MMP-3) is the most important protease involved in RA inflammation which may play a role in the development of cardiovascular events. Antibodies against oxidized low-density lipoprotein (oxLDL) are known to be involved in the development of inflammation and atherosclerosis. Specific role of MMP-3 and antibodies against oxLDL in cardiac pathology in RA patients (pts) is not well investigated.

Objectives To compare MMP-3 and oxLDL-IgG antibody levels, as well as lipid profiles in pts with active RA and healthy controls.

Methods Thirty nine RA pts (33 women and 6 men, median age 56,5 [49; 65] years), with active arthritis (mean disease duration 96 [48; 190] months; DAS28 5,8 [5,3;6,3]; HAQ 1,8 [1,3; 2,2]) were enrolled in the study. Twenty three pts (59%) received methotrexate, 5 (13%) – the combination of methotrexate with oral glucocorticoids, 10 (26%) - oral glucocorticoids monotherapy.

The control group consisted of 29 volunteers (21 women and 8 men, median age 58,5 [53; 62] years). Serum MMP-3 and oxLDL-IgG levels were measured by enzyme-linked immunosorbent assay (ELISA).

Results Elevated MMP-3 levels were detected more frequently in RA pts (31/39 (79%)) vs healthy controls (2/29 (7%), p<0,0001). MMP-3 concentrations were higher in RA pts (57,0 [36,6; 114,3ng/ml), than in the control group subjects (13,4 [9,9; 20,4]mg/ml, p <0,0001). MMP-3 levels demonstrated significant correlation with ESR (r =0,64, p <0,05) and CRP (r =0,52, p<0,05) values.

OxLDL-IgG levels in RA pts and healthy controls did not differ significantly (290,3 [111,3; 608,6] mU/ml, and 228,1 [125,1; 338,8] mU/ml, respectively p>0,05). Rates of dyslipidemia were similar in RA pts (23/39 (59%) and control group subjects (15/29 (52%). Concentrations of lipids were also similar in both groups and were as follows: total cholesterol was 5,2 [4,9; 6,2] mmol/l in RA pts and 6,3 [5,1; 6,6] mmol/l in the control group; HDL cholesterol - 1,7 [1,4; 2,0] mmol/l and 1,7 [1,5; 2,1] mmol/l, LDL cholesterol - 3,3 [2,8; 4,0] mmol/l and 3,6 [3,0; 4,0] mmol/l, triglycerides - 1,3 [1,0; 1,6] mmol/l and 1,4[1,1; 1,8] mmol/l, the atherogenic index of plasma - 2,4 [1,8; 2,8] and 2,4 [1,9; 3,0], respectively. Showed no correlation between the levels of oxLDL-IgG and lipids in both groups. In the RA group, concentrations of HDL cholesterol were negatively correlated with MMP-3 (r=-0,5, p<0,05), C-reactive protein (r=-0,53, p<0,05), and DAS28 (r=-0,4, p<0,05).

Conclusions RA pts exhibited higher serum MMP-3 levels than healthy individuals. OxLDL-IgG levels were similar in RA pts and healthy subjects. Obtained results suggest that MMP-3 and CRP may produce a negative impact on HDL-cholesterol levels in patients with active RA.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.